1.080SEK-6.74%Mkt Cap: 121.86M SEKP/E: —Last update: 2026-05-13
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal strom…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
P/B2.41
P/S12.39
EV/EBITDA-2.59
EV/Revenue9.75
EPS (TTM)-0.43
EPS (Forward)—
Cash Flow & Leverage
FCF Yield—
FCF Margin—
Operating CF-37.78M SEK
CapEx (TTM)82.92K SEK
Net Debt/EBITDA0.70
Net Debt-26.03M SEK
Technical
SMA 501.234 (-12.4%)
SMA 2001.077 (+0.3%)
Beta0.65
S&P 52W Chg24.23%
Avg Vol (30d)728.35K
Avg Vol (10d)885.78K
Technical Indicators
RSI (14)38.7
MACD-0.0310
MACD Signal-0.0306
MACD Hist.-0.0004
BB Upper1.377 SEK
BB Middle1.199 SEK
BB Lower1.021 SEK
BB Width29.71%
ATR (14)0.1243 SEK
Vol Ratio (20d)2.10x
52W Range
0.630039% of range1.784
52W High1.784 SEK
52W Low0.6300 SEK
Profitability
Gross Margin16.38%
EBITDA Margin0.00%
Profit Margin-395.19%
Oper. Margin-761.16%
ROE-77.77%
ROA-61.57%
Revenue Growth-41.00%
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio5.16
Quick Ratio3.92
Book Value/Sh0.4540 SEK
Cash/Share0.2340 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.111.39M
Float86.02M
Insiders30.93%
Institutions6.56%
Analyst Consensus
Rating—
Target (Mean)3.500 SEK
Target Range3.500 SEK – 3.500 SEK
# Analysts1
Company
Market Cap121.86M SEK
Enterprise Value95.83M SEK
Revenue (TTM)9.83M SEK
Gross Profit1.63M SEK
Net Income (TTM)-39.35M SEK
Revenue/Share—
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
Last Price1.080 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—